The peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphoma. The overall prognosis is poor with high risk of relapse after the first-line treatment. The 61st American Society of Hematology (ASH) Annual Meeting has covered many treatment advances of PTCL, especially for relapsed/refractory patients. The main contents include histone deacetylase inhibitors (HDACi), farnesyl transferase (FT) inhibitors, dual inhibitors of SYK/JAK signaling pathway, PI3K inhibition agent, programmed death 1 (PD-1) monoclonal antibody, anti-CD38 monoclonal antibody, and EZH1/2 dual inhibitor. New protocols and drugs have brought hope for relapsed/refractory PTCL patients.